Poor
Partially Aligned
Patient Risk:
Low
Summary
Only one of four extracted claims is supported by the provided FDA label section (11 DESCRIPTION). The remaining three claims are not supported by the provided label content and include non-label assertions (pricing/availability/country dispensing rules) that cannot be verified from the supplied section.
Category Scores
Accurate Statements
Viagra contains the active ingredient sildenafil.
11 DESCRIPTION (states VIAGRA is sildenafil citrate and describes sildenafil citrate as the therapy’s active ingredient)
Unsupported Statements
Other sildenafil products may cost less than brand Viagra.
Not addressed in the provided FDA label section (11 DESCRIPTION); pricing/cost comparisons are not supported.
Prices and availability of sildenafil products differ by brand and regulatory approvals.
Not addressed in the provided FDA label section; availability/pricing/regulatory-approval comparisons are not supported.
Viagra is a prescription-only medicine (rules vary by country).
Not addressed in the provided FDA label section; prescription-only status and country-specific dispensing rules are not supported by the supplied label content.
Contradictions
Important Omissions
No evaluation provided for safety-critical label elements (e.g., contraindications, boxed warnings, warnings/precautions, dosage/administration limits, monitoring, or use in specific populations), because the prompt only supplied section 11 DESCRIPTION.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claim concerns the drug’s active ingredient. The unsupported claims are about cost/availability and dispensing rules and do not directly assert dosing or safety-critical information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Three claims are not supported by the provided FDA label section (11 DESCRIPTION) and include non-label assertions (pricing/availability/country-specific prescription rules).
Suggested Improvement
Limit claims to label-supported statements from the relevant FDA label sections; if discussing prescription status or other regulatory/dispensing details, cite the correct label section(s) (e.g., US-specific prescribing information/How Supplied). Avoid cost/availability/regulatory-approval comparisons unless explicitly stated in the label.